Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

HKI-272 for HER2-Positive Breast Cancer and Brain Metastases

This study is currently recruiting participants. (see Contacts and Locations)
Verified May 2016 by Dana-Farber Cancer Institute
Sponsor:
Collaborator:
Translational Breast Cancer Research Consortium
Information provided by (Responsible Party):
Rachel Freedman, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT01494662
First received: December 14, 2011
Last updated: May 23, 2016
Last verified: May 2016